Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
出版年份 2019 全文链接
标题
Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
作者
关键词
-
出版物
Diabetes Therapy
Volume 10, Issue 6, Pages 2219-2231
出版商
Springer Science and Business Media LLC
发表日期
2019-10-16
DOI
10.1007/s13300-019-00708-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
- (2019) Yuichiro Ito et al. Diabetes Therapy
- Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
- (2019) Rimei Nishimura et al. BMJ Open
- Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
- (2019) Ichiro Nakamura et al. ADVANCES IN THERAPY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Japanese Clinical Practice Guideline for Diabetes 2016
- (2018) Masakazu Haneda et al. Journal of Diabetes Investigation
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
- (2017) Lubin Xu et al. PeerJ
- Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study
- (2016) Koutaro Yokote et al. EXPERT OPINION ON PHARMACOTHERAPY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
- (2015) Takashi Kadowaki et al. ADVANCES IN THERAPY
- A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
- (2015) S. Ikeda et al. DIABETES OBESITY & METABOLISM
- Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
- (2015) E. Araki et al. DIABETES OBESITY & METABOLISM
- Guidelines for good pharmacoepidemiology practice (GPP)
- (2015) PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
- (2015) Yutaka Seino et al. Journal of Diabetes Investigation
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
- (2014) Yukio Tanizawa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
- (2014) Nobuya Inagaki et al. Journal of Diabetes Investigation
- Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
- (2014) Kohei Kaku et al. Diabetes Therapy
- Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
- (2013) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Development of a Database of Health Insurance Claims: Standardization of Disease Classifications and Anonymous Record Linkage
- (2010) Shinya Kimura et al. JOURNAL OF EPIDEMIOLOGY
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started